Ka la 24 Pulungoana 2021, Kintor Pharma o phatlalalitse hore Tsamaiso ea Naha ea Lihlahisoa tsa Bongaka ea China (NMPA) e khantšitse protocol bakeng sa thuto ea bohlokoa ea mohato oa boraro oa KX-826.
Ka la 20 Tšitoe 2021, kopano ea ho raha lipakeng tsa bafuputsi ba bohlokoa bakeng sa teko ea tleliniki ea KX-826 phase III e ile ea tšoaroa ka katleho. Sepetlele sa Batho sa Univesithi ea Peking le Sepetlele sa Huashan se ikopantseng le Fudan University li etelletse nyeoe pele, 'me lipetlele tse 26 li ne li tla nka karolo. Ka mor'a ho atleha ho tsamaisa teko ea bongaka ea KX-826 Chaena bakeng sa phekolo ea AGA, Moprofesa Zhang Jianzhong oa Peking University People's Hospital le Moprofesa Yang Qinping oa Huashan Hospital e ikopantseng le Fudan University ba sebelisana hape ho ba bafuputsi ba ka sehloohong. li-PIs tse etellang pele) tsa teko ea bohlokoa ea Phase III Clinical Trial ea KX-826. Sebokeng sa bafuputsi, litsebi tse ka bang 100 tse tsoang lipetleleng tse 26 ho pholletsa le Chaena li ile tsa mamela tlaleho e mabapi le katleho le polokeho ea teko ea bongaka ea KX-826's Phase II. Moprofesa Zhang Jianzhong o phethetse seboka mme a khothaletsa PI e 'ngoe le e' ngoe hore e kenye letsoho thutong ena ea bohlokoa ka boleng bo holimo le ka bokhabane.
Dr. Youzhi Tong, mothehi, Molula-setulo, le Ofisiri e ka Sehloohong ea Kintor Pharma, o itse, "Sehlopha sa Kintor se sebelitse ka katleho e phahameng ho tloha ka tumello ea NMPA ho ea tekong ea pele ea teko ea kliniki ea mohato oa III hoo e ka bang khoeli e le 'ngoe. Teko ena ea bongaka ea karolo ea III e tla etsoa litsing tse 26 tse holimo tsa bongaka tsa letlalo ho pholletsa le China. Re lebeletse ho phethela boingoliso ba lithuto tse 416 tse reriloeng ka Phuptjane 2022, le tlhahlobo e latelang ea bongaka (thuto ea likhoeli tse 6 + le ho latela khoeli e 1) pele selemo se fela. Ka sepheo sa ho phethela teko ea kliniki ea karolo ea III selemong sena, re potlakisa ts'ebetso mme re lebelletse hore KX-826 e tla thusa bakuli ba lefats'e kapele kamoo ho ka khonehang. "
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- After successfully co-leading the phase II clinical trial of KX-826 in China for the treatment of AGA, Professor Zhang Jianzhong from Peking University People’s Hospital and Professor Yang Qinping from Huashan Hospital affiliated to Fudan University cooperate again to be the leading principal investigators (leading PIs) of the pivotal Phase III Clinical Trial of KX-826.
- At the investigator meeting, nearly 100 experts from 26 hospitals across China listened to the report on the efficacy and safety of the KX-826’s Phase II clinical trial.
- With the goal of completing the phase III clinical trial this year, we are speeding up the process and expecting that KX-826 would benefit global patients as soon as possible.
